| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Florian Hoffmann | |
| Gordon Cook | |||
| Marie von Lilienfeld-Toal | |||
| Ralf Bargou | |||
| Axel Glasmacher | |||
| Ralph Naumann | |||
| Corinna Hahn-Ast | |||
| Kerstin Furkert | |||
| P2860 | cites work | Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. | Q55042799 |
| An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma | Q79839141 | ||
| Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial | Q30433139 | ||
| Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma | Q33376008 | ||
| A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma | Q36381565 | ||
| Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma | Q37038414 | ||
| Thalidomide and dexamethasone combination for refractory multiple myeloma | Q43719056 | ||
| Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. | Q44214963 | ||
| Thalidomide and dexamethasone for resistant multiple myeloma | Q44461621 | ||
| Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma | Q45009410 | ||
| Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival | Q45296702 | ||
| The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio | Q46634193 | ||
| Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma | Q46738036 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| thalidomide | Q203174 | ||
| dexamethasone | Q422252 | ||
| multiple myeloma | Q467635 | ||
| systematic review | Q1504425 | ||
| biomedical investigative technique | Q66648976 | ||
| antineoplastic combined chemotherapy protocols | Q66764603 | ||
| phase II clinical trial | Q42824440 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 247-252 | |
| P577 | publication date | 2008-07-10 | |
| 2008-10-01 | |||
| P1433 | published in | European Journal of Haematology | Q15765799 |
| P1476 | title | A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma | |
| P478 | volume | 81 |
| Q52686509 | Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma. |
| Q38658649 | Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma. |
| Q38182683 | Current strategies for treatment of relapsed/refractory multiple myeloma |
| Q57076619 | Effect of Thalidomide on Clinical Remission in Children and Adolescents with Ulcerative Colitis Refractory to Other Immunosuppressives |
| Q35104606 | Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: a systematic review and meta-analysis |
| Q35172445 | Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma |
| Q39584752 | Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma |
| Q58563417 | Evaluating Treatment Strategies for Spinal Lesions in Multiple Myeloma: A Review of the Literature |
| Q56982314 | Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma |
| Q38681463 | Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group |
| Q37970946 | Management of treatment-emergent peripheral neuropathy in multiple myeloma. |
| Q37753347 | Management of treatment-related adverse events in patients with multiple myeloma |
| Q92276356 | Managing treatment-related peripheral neuropathy in patients with multiple myeloma |
| Q28477357 | Neuropathic pain and psychological morbidity in patients with treated leprosy: a cross-sectional prevalence study in Mumbai |
| Q37843770 | New immunomodulatory drugs in myeloma |
| Q38069614 | Novel immunomodulatory compounds in multiple myeloma |
| Q53245450 | Percutaneous vertebroplasty in multiple myeloma: prospective long-term follow-up in 106 consecutive patients. |
| Q37655019 | Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study |
| Q38111390 | Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist |
| Q38255265 | Pomalidomide for multiple myeloma |
| Q34165935 | Pomalidomide therapy for multiple myeloma and myelofibrosis: an update |
| Q36148528 | Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma |
| Q36382493 | Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study |
| Q35200765 | Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. |
| Q37800884 | The Belgian 2010 consensus recommendations for the treatment of multiple myeloma |
| Q40813914 | The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea. |
| Q37709559 | The development and pharmacology of proteasome inhibitors for the management and treatment of cancer |
| Q36612613 | The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development |
| Q37851944 | The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information. |
| Q55513961 | The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma. |
| Q38268525 | Therapy-related peripheral neuropathy in multiple myeloma patients. |
| Q37328204 | Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs). |
| Q39369772 | Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting. |
| Q47770089 | Triplet vs. doublet drug regimens for managing multiple myeloma. |
Search more.